PROCEPT BioRobotics Corporation Common Stock (PRCT) — Analysis Summary
PROCEPT BioRobotics Corporation Common Stock (PRCT) has a market cap of $1.20B with year-over-year revenue growth of +37.2%. Net margin stands at -31.0%. The stock trades at a P/E ratio of -11.0.
Key Takeaways
- Revenue changed +37.2% year-over-year
- Net margin of -31.0%
- P/E ratio of -11.0
Compared to other companies in the SURGICAL & MEDICAL INSTRUMENTS & APPARATUS sector, PRCT posted revenue growth of +37.2% and trades at a P/E of -11.0.
PROCEPT BioRobotics Corporation Common Stock (PRCT)
UPDATED — ET · MARKET DATA POLYGON · FINANCIALS SEC EDGAR
Red Flags & WarningsHigh Risk Signals
Multiple material red flags are active and deserve closer underwriting before relying on any valuation output.
Interest coverage at -32.9x — earnings do not cover interest payments
Operating margin at -33.9% — material operating losses
Net margin at -32.5% — significant losses
The latest filing shows negative free cash flow.
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
Sector
SURGICAL & MEDICAL INSTRUMENTS & APPARATUS
Employees
888
Headquarters
SAN JOSE, CA
Exchange
XNAS
Systematic competitive advantage assessment based on 4yr data
This assessment is based on quantitative analysis of historical financial data and does not constitute investment advice. Moat ratings may change with industry and competitive dynamics.
First version surfaces recent SEC Forms 3, 4, and 5 activity. It does not yet parse individual buy/sell transactions.
Capital Structure
Cash Flow
Disclaimer: This is not financial advice. Data sourced from SEC EDGAR and Polygon.io. Past performance does not guarantee future results. Always conduct your own research before making investment decisions.